Christian Klemt sells 1,687 shares of uniQure (NASDAQ:QURE)
uniQure (NASDAQ:QURE – Get Rating) Chief Financial Officer Christian Klemt sold 1,687 shares in a trade that took place on Thursday, June 16. The shares were sold at an average price of $13.20, for a total transaction of $22,268.40. Following the transaction, the CFO now owns 104,688 shares of the company, valued at $1,381,881.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink.
QURE stock traded at $1.10 on Tuesday, hitting $15.21. The company’s stock had a trading volume of 811,059 shares, compared to an average volume of 541,932. The company has a fifty-day simple moving average of $15.12 and a two-hundred-day simple moving average of 17 $.68. uniQure has a 12 month minimum of $12.52 and a 12 month maximum of $38.80. The company has a market capitalization of $709.52 million, a PE ratio of 2.21 and a beta of 1.13. The company has a debt ratio of 0.19, a quick ratio of 12.94 and a current ratio of 12.94.
uniQure (NASDAQ:QURE – Get Rating) last announced its quarterly results on Monday, May 2. The biotech company reported ($1.00) EPS for the quarter, missing analyst consensus estimates of ($0.67) by ($0.33). uniQure had a return on equity of 54.85% and a net margin of 61.76%. The company posted revenue of $1.79 million in the quarter, compared to $51.23 million expected by analysts. As a group, research analysts expect uniQure to post earnings per share of -3.54 for the current fiscal year.
QURE has been the subject of a number of recent research reports. Stifel Nicolaus cut his price target on uniQure shares from $66.00 to $37.00 in a Thursday, May 5 research report. UBS Group upgraded uniQure shares from a “neutral” rating to a “buy” rating and set a price target of $40.00 on the stock in a Thursday, March 17 research report. Chardan Capital cut its price target on uniQure shares from $95.00 to $65.00 in a Wednesday, March 30 research report. StockNews.com upgraded uniQure’s shares from a “sell” rating to a “hold” rating in a Wednesday, June 8 report. Finally, Goldman Sachs Group cut its price target on uniQure shares from $59.00 to $51.00 and set a “buy” rating on the stock in a Tuesday, May 24 report. One research analyst gave the stock a hold rating and eight gave the company a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.43.
A number of hedge funds have recently changed their positions in the stock. Meeder Asset Management Inc. bought a new position in uniQure during the first quarter worth $27,000. First Quadrant LP CA bought a new position in shares of uniQure in the 4th quarter for a value of approximately $37,000. PNC Financial Services Group Inc. increased its stake in uniQure by 152.5% in Q1. PNC Financial Services Group Inc. now owns 2,038 shares of the biotech company worth $37,000 after buying 1,231 more shares last quarter. Future Financial Wealth Management LLC purchased a new stake in uniQure in Q4 worth approximately $43,000. Finally, Nisa Investment Advisors LLC purchased a new stake in uniQure in Q4 worth approximately $45,000. 81.35% of the shares are held by institutional investors.
uniQre company profile (Get an assessment)
uniQure NV, a gene therapy company, is engaged in the development of treatments for patients suffering from genetic diseases and other devastating illnesses. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in the pivotal phase III HOPE-B trial for the treatment of hemophilia B. The company is also engaged in the development of AMT-130, a gene therapy that is in a phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in a phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
Get news and reviews for uniQre Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for uniQre and related companies with MarketBeat.com’s free daily email newsletter.